LUGANO

Jul 31, 2019

Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada

Jul 02, 2019

Acquisition of the business aviation activities of RUAG in Geneva and Lugano by Dassault Aviation

Jun 19, 2019

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

Dec 21, 2018

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Dec 03, 2018

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

Nov 27, 2018

Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer

Jan 11, 2018

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)

Aug 02, 2017

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Jun 05, 2017

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia